AccurKardia
  • AccurECG 2.0
  • Novel
  • Who we are
    • In the media
    • Research
Partner with us
AccurKardia
  • AccurECG 2.0
  • Novel
  • Who we are
    • In the media
    • Research
Partner with us

Committed to make our technology available for independent clinical and scientific research

DateTypePublicationTopic
  • September 2026Sep 2026AbstractPreoperative AI-ECG analysis predicts paravalvular leak after transcatheter aortic valve replacement …Aortic stenosis
  • September 2026Sep 2026AbstractMulti-hospital external validation of lead-I ECG AI model for the detection of moderate-to-severe hyperkalemia in chronic kidney …Hyperkalemia
  • February 2026Feb 2026ResearchValidation and Longitudinal Trajectory Analysis of an AI-Based ECG Model for Aortic Stenosis: From Community Screening to …European Heart Journal – Digital HealthAortic stenosis
  • November 2025Nov 2025ResearchSingle-Lead ECG AI Model Accurately Predicts Moderate-to-Severe Hyperkalemia in Multi-Hospital External …Circulation · AHA Scientific Sessions 2025Hyperkalemia
  • September 2025Sep 2025ResearchLongitudinal ECG trajectories identify high-risk aortic stenosis phenotypes years prior to TAVRESC Congress 2025Aortic stenosis
  • September 2025Sep 2025ResearchPeriprocedural changes in an AI-based ECG model predict post-TAVR clinical outcomesESC Congress 2025Aortic stenosis
  • February 2025Feb 2025White paperAccurKardia’s AK-AVS represents a new paradigm for AS screening by utilizing existing ECGs within hospital system EHRs …AccurKardiaAortic stenosis
  • September 2024Sep 2024ResearchPredicting Aortic Stenosis in the Community using an Artificial Intelligence Model for 12-lead Electrocardiograms …Heart RhythmAortic stenosis
  • September 2022Sep 2022ResearchComparison Between QT and Corrected QT Interval Assessment by an Apple Watch With the AccurBeat Platform and by a 12-Lead …JMIR Formative ResearchQT interval

Evidence is built together.

Researchers and clinicians

Collaborate with us on validation studies, data partnerships and new indications.

Collaborate on research

Partners and investors

Talk to us about bringing ECG-based biomarkers into clinical practice at scale.

Talk to the team
AccurKardia

Applications

  • AccurECG 2.0
  • Novel

Company

  • Who We Are
  • News
Regulatory and research-use information

The AccurECG™, AK-AVS™, and AK+ Guard™ are registered trademarks of AccurKardia, Inc., with all intellectual property rights owned by AccurKardia, Inc.

For detailed technical AccurECG requirements, relevant disclosures, and approved indications for use, please refer to the U.S. FDA 510(k) K252361 summary and product labeling.

AccurECG results are not intended to serve as the sole basis for diagnosis. The system is offered to qualified healthcare professionals on an advisory basis only and should be used in conjunction with the physician’s expertise, knowledge of ECG patterns, patient background, clinical history, symptoms, and other diagnostic information.

AK-AVS™ and AK+ Guard™ are currently for research use only and have not been cleared or approved by the US FDA for use in the United States. This technology is under development and intended solely for investigational purposes. It should not be used for clinical diagnosis, treatment, or disease screening at this time. AK-AVS™ and AK+ GuardTM are currently patent pending.

The information provided on this website is for informational purposes only and does not constitute medical, legal, or professional advice. Always consult a qualified healthcare provider for clinical decision-making.

AK-AVS and AK+ Guard are investigational devices. They are not cleared or approved by the FDA and are not available for commercial use. AccurECG 2.0 is FDA cleared for its stated intended use only.

© 2026 AccurKardia, Inc.

  • Terms of Use
  • Privacy Policy